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Abstract
Background: Evidence‐based treatments for post‐traumatic stress disorder (PTSD)
have poor uptake and remission rates, suggesting that alternative treatments are
needed. Morning bright light may be an effective treatment for PTSD given its
established effects on mood and sleep, however, there are no published trials.
Methods: We conducted a placebo‐controlled pilot trial of a wearable light device,
the Re‐timer®, for individuals with probable PTSD. Individuals were randomly
assigned to the active Re‐timer® (n = 9) or a placebo Re‐timer® dimmed with neutral
density filters (n = 6). Participants self‐administered the treatment at home 1 hr each
morning over 4 weeks. PTSD and depression symptoms were assessed at pre‐ and
post‐treatment.
Results: The Re‐timer® was well tolerated and the perceived benefit was high, though
treatment adherence was only moderate. Those in the active group were more likely
to achieve a minimal clinically important change in PTSD and depression symptoms
and had larger symptom reductions than those in the placebo group
Conclusions: A wearable morning light treatment was acceptable and feasible for
patients with probable PTSD. This study provides initial proof‐of‐concept that light
treatment can improve PTSD. A larger trial is warranted to establish treatment
efficacy. NCT#: 03513848
K E YWORD S
bright light, device, post‐traumatic stress disorder (PTSD), randomized controlled trial, trauma,
treatment
1 | INTRODUCTION
The mental health burden of post‐traumatic stress disorder (PTSD) is
costly for individuals and society (Kessler, 2000). Trauma‐focused
psychotherapies are considered to be first‐line treatments for PTSD
(Lee et al., 2016); however, evidence suggests that many individuals
fail to receive these treatments let alone a therapeutic dose (Hoge
et al., 2014). Treatment uptake is poor for several reasons including
avoidance and lack of availability (Kantor, Knefel, & Lueger‐Schuster,
2017). Moreover, many individuals remain symptomatic despite
receiving treatment (Bradley, Greene, Russ, Dutra, & Westen, 2005).
Alternative treatments are needed that are effective, acceptable, and
accessible to patients.
Morning light treatment may be an effective treatment for PTSD.
Although there is limited research examining circadian disturbances
in PTSD, evidence suggests that an evening chronotype is associated
with worse PTSD symptoms (Hasler, Insana, James, & Germain, 2013;
Yun, Ahn, Jeong, Joo, & Choi, 2015). Later circadian timing (phase
delay) is also associated with worse mood and sleep quantity/quality
(Emens, Lewy, Kinzie, Arntz, & Rough, 2009; Hasler, Buysse, Kupfer &
Germain, 2010), which are core symptoms of PTSD (Friedman, 2013;
Spoormaker & Montgomery, 2008). Morning bright light treatment
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effectively advances circadian timing (i.e., shift toward morningness;
St. Hilaire et al., 2012), and meta‐analyses have shown morning light
treatment is effective for nonseasonal depression (Al‐Karawi &
Jubair, 2016), and can meaningfully improve subjective and objective
sleep (van Maanen, Meijer, van der Heijden, & Oort, 2016). However,
to our knowledge, there are no published studies examining the
effects of morning bright light treatment for PTSD.
In addition to light's potential therapeutic effects, light treatment
is safe and noninvasive with minimal side effects. Although some side
effects have been reported (headache, eyestrain, nausea, and
agitation), these often spontaneously remit and patients rarely
discontinue because of the side effects (Pail et al., 2011; Terman &
Terman, 2005). Light treatments are also typically self‐administered,
which makes them easily disseminable and scalable. Early research
on light treatment used light boxes, however, newer wearable
devices make it more feasible for patients to receive therapeutic
doses as individuals can be ambulatory while receiving light
treatment. The goal of this randomized controlled pilot trial was to
evaluate the acceptability and feasibility of a wearable morning light
treatment for probable PTSD, and make a preliminary assessment of
the treatment's effectiveness in improving PTSD symptoms.
2 | METHODS
2.1 | Participants and procedures
A total of 15 participants with probable PTSD (i.e., PTSD symptoms
were established using a self‐report measure rather than a gold‐
standard clinical assessment) were randomly assigned to active
(n = 9) and placebo (n = 6) conditions. A CONSORT diagram of
participant flow is presented in Figure 1. Participant demographics
are reported in Table 1.
Participants had to meet the following inclusion criteria: PTSD
Checklist for DSM‐5 score >33 (Bovin et al., 2016) rated based on
an index trauma that met DSM‐5 criterion A for PTSD; 18–70
years old; and fluent in English. Exclusion criteria are reported in
Table 2. When scheduling participants, study staff ensured that
participants would not be engaged in the protocol during the bi‐
annual time change for daylight saving time or any special events
that might disrupt sleep.
2.2 | Procedures
Participants were recruited from local advertisements. An initial
phone screen was conducted to establish preliminary inclusion
criteria; those who appeared eligible were invited for an in‐person
screening visit. All participants provided written informed consent
before any study procedures. During the screening visit, participants
completed a series of questionnaires and were given detailed
instructions regarding the study procedures. Eligible participants
who chose to enroll in the study completed a pretreatment visit (Day
1; visit 1), which included a urine drug test, a breathalyzer test, and
questionnaires. Those who failed the drug or breathalyzer tests were
excluded from the study. Those who passed received a wrist activity
monitor, daily sleep logs and event logs at the Day 1 visit and were
told to sleep ad lib at home, following their usual sleep schedule. On
Day 8 (visit 2), participants completed a baseline session in which
they completed questionnaires and were randomized 1:1 to the
bright (active) or dim (placebo) Re‐timer® using a simple randomiza-
tion scheme. Participants were instructed on how to use the Re‐
timer® and only saw the Re‐timer® device they were assigned (single‐
blinded).
On Day 9, subjects began 4 weeks of self‐administered bright
light treatment at home. Participants were told to use the Re‐timer®
for 1 hr each morning starting at their usual wake time or up to 1 hr
earlier if required to fit into their daily schedule (determined from
baseline week of wrist actigraphy) and to maintain their habitual
sleep duration. Participants returned to the lab weekly for 4 weeks
(visits 3–6) for repeat questionnaires and review of their treatment
adherence (including immediate feedback on the basis of their data
to encourage adherence). Participants were compensated $75 for
each for visits 2 through 5 as well as $150 for visit 6 in the form of a
check or gift cards. This study was approved by the Institutional
Review Board at Rush University Medical Center.
F IGURE 1 CONSORT diagram of
participant flow. PTSD: post‐traumatic
stress disorder
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2.3 | Re‐timer® and placebo devices
The Re‐timer® is commercially available and permits ambulation
while receiving light from LEDs positioned below the eyes. The Re‐
timer® can be worn over glasses and does not substantially interfere
with vision. The LEDs emit green light (~500 nm, 230 µW/m2, 500
lux), close to the peak sensitivity of circadian photoreceptors
(~480 nm; LeGates, Fernandez, & Hattar, 2014). The Re‐timer® has
previously been shown to shift circadian timing (Lovato &
Lack, 2016).
We created a placebo device using neutral density filters to
reduce the light intensity to a level that will not shift circadian timing
(irradiance 3 μW/m2, 7 lux, Zeitzer, Dijk, Kronauer, Brown, &
Czeisler, 2000). The placebo (dim) Re‐timer® appears identical to
those on the Re‐timer® website.
3 | MEASURES
All self‐report measures were collected at pre‐treatment (visit 2) and
post‐treatment (visit 6). Objective sleep and treatment adherence
was assessed throughout the study.
3.1 | Post‐traumatic stress disorder checklist for
DSM‐5 (PCL‐5; Weathers et al., 2013)
This 20‐item self‐report measure asks participants to rate how much
they are bothered by DSM‐5 PTSD symptoms based on their index
trauma. Signal detection analyses have shown that a score of 31–33
had the highest efficiency for diagnosing PTSD (Bovin et al., 2016). At
the screening visit, participants were asked to rate their symptoms
for the past month to establish study eligibility. At visits 2 and 6,
TABLE 1 Sample characteristics
Total
sample Active Placebo
Variable M (SD) M (SD) M (SD)
Age 44.93
(11.83)
40.89
(9.36)
51.00
(13.33)
Adherence: Days initiated
treatment
21.5 (6.1) 19.67
(5.81)
24.17
(6.01)
Adherence: Minutes per
treatment day in prescribed
window
35.2 (6.3) 32.45
(5.30)
39.22
(5.81)
Variable n (%) n (%) n (%)
Male 7 (46.7) 5 (55.6) 2 (33.3)
Ethnicity
Non‐Hispanic 11 (73.3) 6 (66.7) 5 (83.3)
Hispanic/Latino 4 (26.7) 3 (33.3) 1 (16.7)
Race
White 4 (26.7) 4 (44.4) 0 (0.0)
Black/African American 8 (53.3) 3 (33.3) 5 (83.3)
Mixed 2 (13.3) 1 (11.1) 1 (16.7)
Decline to answer 1 (6.7) 1 (11.1) 0 (0.0)
Marital status
Single 12 (80.0) 7 (77.8) 5 (83.3)
Married/domestic
partnership/engaged
3 (20.0) 2 (22.2) 1 (16.7)
Highest degree
Less than high school 2 (13.3) 2 (22.2) 0 (0.0)
High school/GED 4 (26.7) 1 (11.1) 3 (50.0)
Vocational/associates degree/
some college
6 (40.0) 5 (55.5) 1 (16.7)
Baccalaureate or master's
degree
3 (20.0) 1 (11.1) 2 (33.3)
Index trauma type
Physical/sexual assault 5 (33.3) 2 (22.2) 3 (50.0)
Being shot/shot at 4 (26.7) 4 (44.4) 0 (0.0)
Witnessing serious harm or
death of others
3 (20.0) 2 (22.2) 1 (16.7)
Combat 2 (13.3) 1 (11.1) 1 (16.7)
Motor vehicle accident 1 (6.7) 0 (0.0) 1 (16.7)
Total sample N = 14. Active group n = 9. Placebo group n = 6. “Adherence:
Days initiated treatment” refers to the number of days that participants
completed part or all of the morning light treatment out of the 28
treatment days. “Adherence: minutes per treatment day in prescribed
window” refers to the minutes of light that participants received in the
treatment window on days when they initiated treatment.
TABLE 2 Exclusion criteria
Exclusion criteria
Past 6‐month substance use disorder
Lifetime psychotic or bipolar disorder
Lifetime diagnosis of winter depression
Significant suicidal ideation or behaviors in the past 6 months
Severe hearing and memory problems
Cognitive impairment that would interfere with consent
Pending legal cases or litigation
Initiation of psychotherapy in the past 30 days
Engaged in evidence‐based psychotherapy for PTSD
Serious unstable medical condition likely to result in hospitalization in
the next year
Chronic migraine triggered by bright light
Vision problems, retinal disease, history of eye surgery, or history of
light treatment
Photosensitizing medication use
Unstable dose of psychiatric medication (hypnotics, sleep aids, and
antidepressants must be stable for 30 days before and during the
study)
High risk for sleep apnea (Netzer, Stoohs, Netzer, Clark, & Strohl,
1999) or restless leg syndrome (Hening & Allen, 2003)
Worked night shift in the past month
Pregnant, trying to get pregnant, or breastfeeding
Travel outside the study time zone in the past month
Note. PTSD: post‐traumatic stress disorder
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participants were asked to rate their symptoms for the past week to
detect changes that occurred during the intervention. A 10‐point
improvement is considered to be a minimal clinically important
difference (MCID) for the DSM‐IV version of the scale (PTSD:
National Center for PTSD, 2017). Given that there are not updated
standards for the PCL‐5, we used that as our threshold. Cronbach's
alpha was 0.90 at both pretreatment and post‐treatment.
3.2 | Patient health questionnaire‐9 (Kroenke,
Spitzer, & Williams, 2001)
The Patient health questionnaire‐9 (PHQ‐9) assesses the severity of
depression symptoms over the past 2 weeks. A 5‐point improvement
on the PHQ‐9 has been established as a MCID (Löwe, Unützer,
Callahan, Perkins, & Kroenke, 2004). Cronbach's alpha was 0.72 at
pretreatment and 0.83 at post‐treatment.
3.3 | Pittsburgh sleep quality index (Buysee,
Reynolds, Monk, Berman, & Kupfer, 1989)
The Pittsburgh sleep quality index (PSQI) is a 19‐item self‐rated
instrument that measures seven domains of sleep complications over
the past month. Items from each domain are rated on a 0–3 scale and
summed to create a global score. Higher composite scores signify
poorer sleep quality.
3.4 | Objective sleep measures
Between visits 1 and 6, participants were asked to wear a wrist
actigraphy monitor (30 s epochs, Actiwatch Spectrum, Respironics,
Bend, OR) on their nondominant wrist, complete sleep logs, and press
the event marker on the monitor before and after sleep each day.
The data were analyzed with the Actiware 6.0.9 program (Respiro-
nics). The setting of nightly rest intervals for the analysis was guided
by the event markers, sleep logs, light data, and activity levels (Patel
et al., 2015). Objective actigraphy estimates of sleep onset time
(clock time of the first epoch scored as sleep in each rest interval),
wake time (clock time of the last epoch scored as sleep in each rest
interval), total sleep time (TST, number of minutes scored as sleep in
each rest interval), and wake after sleep onset (WASO, number of
minutes scored as wake between sleep onset and wake time) were
extracted for each study day, then averaged for the baseline week
and last treatment week.
3.5 | Treatment adherence
Adherence was evaluated using light and activity readings from a
monitor (30 s epochs, Actiwatch Spectrum, Respironics) attached
to the inside of the Re‐timer®. These readings allowed us to
evaluate green light to determine Re‐timer® on/off times and
activity to confirm that the Re‐timers® were worn at the assigned
times.
3.6 | Treatment expectancy, perceived benefit, and
blinding
Treatment expectancy was evaluated at the baseline visit after
participants were introduced to their assigned Re‐timer®. Partici-
pants were asked to report, “How much do you expect to benefit
from the 4‐week light treatment” on a 10‐point Likert‐type scale
from 0 (not at all) to 10 (a lot). Perceived benefit was evaluated at the
endpoint session. Participants were asked to report, “How much did
you benefit from the 4‐week light treatment” on a 10‐point Likert‐
type scale from 0 (not at all) to 10 (a lot). At the end of treatment,
participants were asked to return an anonymous survey via mail that
asked about their experience in the trial including whether they
thought they were in the active or placebo group.
3.7 | Statistical approach
Given the small sample size for this pilot study, we did not conduct
significance testing using inferential statistics. For expectancy,
perceived benefit, and adherence, we reported the distribution of
these variables in each arm, including the median response. We also
evaluated the degree to which our acceptability/feasibility measures
(expectancy, side effects, attrition, and adherence) met specific
success criteria (Thabane et al., 2010): (a) Overall median treatment
expectancy would be greater than the midpoint of the scale, (b) less
than 38% of the sample would report any side effects (on the basis of
Cascade, Kalali, & Kennedy, 2009), (c) less than 21.2% of the sample
would drop out after initiating treatment (on the basis of Bradley
et al., 2005), and (d) participants would receive a minimum of 12 min
of light therapy per day for the first 2 weeks (on the basis Al‐Karawi
& Jubair, 2016 and Chang et al., 2012). For sleep variables, we
reported descriptive statistics at pre‐ and post‐treatment and
calculated the magnitude of the difference in change from pre‐ to
post‐treatment (calculated as a change score) for the active v.
placebo group using Cohen's d. We calculated similar effect sizes for
our clinical outcome variables (PCL‐5, PHQ‐9) and also evaluated
what percentage of participants in each treatment arm achieved
a MCID.
4 | RESULTS
4.1 | Expectancy, perceived benefit, adherence,
and tolerance
The overall median treatment expectancy was eight, which exceeded
our success criteria of five. All participants in the active group
reported treatment expectancy at or above the midpoint of the scale
(range 5–10, median = 8). Five of six participants in the placebo group
(83.3%) reported treatment expectancy at or above the midpoint of
the scale (median = 7); one participant reported a treatment
expectancy of 0. At the end of treatment, all participants reported
the perceived benefit of the treatment at or above the midpoint of
the scale (median = 7 for both active and placebo groups). Nine of the
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15 participants completed the anonymous feedback survey; all nine
thought they were in the active treatment group.
All participants that were randomized completed the 4‐week
intervention, which met our attrition success criteria. On average,
participants initiated morning light treatment on 21.5 of the 28
treatment days; on days when participants initiated treatment, they
received an average of 35.2 min per day within the prescribed
treatment window (see Table 1). Adherence was similar in the active
and placebo groups. Only three individuals (all in the placebo group)
met our adherence success criteria.
Only one person in the active group (11.1% of active group
participants) reported a mild headache on Day 7 of light treatment,
which met our success criteria. The participant chose to continue
treatment and reported no other headaches throughout the trial. No
participants in the placebo group reported side effects.
4.2 | Changes in sleep
Descriptive statistics for subjective and objective sleep measures are
reported by treatment group in Table 3. Active group participants
reported greater improvements in subjective sleep quality from pre
to post‐treatment than placebo participants; however, this difference
was small (d = 0.29). There was little change in sleep start times in
both groups; however, the placebo group saw a slightly greater
advance in sleep start time relative to the active group (d = 0.29).
Active participants saw a greater advance in wake time relative to
placebo participants (d = 0.68). Correspondingly, active participants
revealed a decrease in TST from pre‐ to post‐treatment of
approximately 36 min, whereas placebo participants revealed no
change in TST, resulting in a large difference in TST change from pre‐
to post‐treatment between the groups (d = 0.77). Active participants
also showed a decrease in WASO from pre‐ to post‐treatment,
indicating greater sleep continuity, whereas placebo participants
showed a slight increase in WASO from pre‐ to post‐treatment. This
resulted in a moderate difference in WASO change between the
groups (d = 0.48).
4.3 | Clinical outcomes
Table 4 reports pre‐ and post‐treatment means and standard
deviations for the outcome measures by the treatment group, the
percentage of participants in each group that achieved a MCID, and
the effect size of the difference in pre‐post change for the active
versus placebo group. A higher proportion of those in the active
group achieved a MCID in PTSD and depression symptoms. On
average, participants in the active group also had larger reductions in
PTSD and depression symptoms from pre‐ to post‐treatment than
those in the placebo group (d = 0.94 and 0.74, respectively).
An issue that emerged is that some participants experienced a
decrease in PTSD symptoms between the screening and the initiation
of morning light treatment. Therefore, not all participants had a PCL‐
5 score >33 when the treatment was initiated. Wortmann et al.
(2016) conducted a psychometric analysis of the PCL‐5 and
evaluated optimally efficient cut scores for the PCL‐5 relative to
various scoring rules established for DSM‐IV PTSD measures. They
reported a score of 25 as the lowest PCL‐5 score that corresponded
to a previously established cut score. Therefore, we conducted a
sensitivity analysis examining change in PTSD symptoms for those
who scored a minimum of 25 points on the PCL‐5 at visit 2 (8 active,
5 placebo). The findings were similar to the original analyses (see
Table 4).
5 | DISCUSSION
This is the first published study evaluating a morning bright light
treatment for individuals with probable PTSD. Our findings indicated
that a 4‐week wearable bright light treatment was acceptable and
feasible for participants. Only 18% (7/38) of individuals who
expressed interest in the study declined to participate. It is unclear
whether these individuals were not interested in the treatment or did
not want to undergo the study procedures. Thus, the treatment
appeared to be acceptable to the majority of potential participants.
Treatment expectancy was high before treatment initiation, suggest-
ing that participants believed that the treatment was plausible and
had the potential to reduce their symptoms. The treatment was also
well tolerated by participants; all those who initiated the treatment
completed the treatment and only one participant in the active group
reported transient side effects.
Our findings do indicate that adherence to a 1 hr treatment
within a prescribed time window may be a challenge for patients.
Patients initiated light therapy on 77% of the treatment days,
TABLE 3 Changes in subjective and objective sleep by the
treatment group
Active (n = 9) Placebo (n = 6)
Pre Post Pre Post
M (SD) M (SD) M (SD) M (SD) | d |
PSQI 8.67
(3.64)
6.67
(3.04)
7.67
(1.37)
6.50
(3.99)
.29
Start
time
24.23
(1.13)
24.10
(1.48)
23.31
(1.11)
22.95
(1.58)
.29
Wake
time
7.72
(1.02)
6.89
(0.94)
7.35
(1.50)
7.00
(1.20)
.68
WASO 66.34
(34.21)
60.08
(33.71)
60.82
(26.57)
61.40
(27.48)
.48
Sleep
time,
min
383.19
(68.49)
347.21
(62.48)
421.35
(46.76)
421.49
(35.71)
.77
Note. PSQI: Pittsburgh sleep quality index; higher scores indicate worse
sleep quality. Start time: time subjects fell asleep in military decimal time.
End time: time subjects woke up in military decimal time. WASO: wake
after sleep onset. Sleep time: total sleep time. d = effect size of the
difference between the active and placebo group in change from pre‐ to post‐
treatment (calculated as a change score). For sleep variables, pre reflects the
average baseline week of sleep before the initiation of light treatment and post
reflects the average week of sleep during Week 4 of light treatment.
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indicating that the 4‐week timeframe was feasible. However, they
only received an average of 35 min per treatment day in the
prescribed window and very few individuals received what could
be considered a minimally active daily course of treatment. It is
important to note that participants may have continued to use
the light treatment outside of the prescribed window and,
therefore, may have gotten a larger dose of treatment than is
indicated by our conservative metric. Moreover, our objective
sleep measures suggested that active group participants experi-
enced a circadian shift with the amount of light received,
evidenced by earlier morning wake times. Thus, future research
examining the minimal dose needed for therapeutic effects is
much needed.
With respect to changes in sleep, the active group showed
expected advances in wake time and decrease in WASO relative to
the placebo group. The decrease in TST was not anticipated, but
appeared to result largely from the earlier awakenings in the active
group. The fact that TST was reduced to less than 6 hr in the active
group at post‐treatment suggests that greater emphasis should be
placed on earlier bedtimes to avoid sleep deprivation when
introducing light treatment. The greater sleep deprivation in the
active group may have contributed to the greater reduction in WASO
(improved sleep continuity) and improvement in subjective sleep
quality in the active group. Nonetheless, our findings suggest that
providers should continue to monitor sleep duration and possible
negative side effects of sleep loss when recommending morning light
treatment.
Clinical outcomes showed that a higher proportion of indivi-
duals in the active group demonstrated a clinically meaningful
improvement in PTSD symptoms relative to the placebo group and
the magnitude of difference in PTSD symptom reduction between
the active and placebo group was large. These findings should be
taken with caution given the small sample size, unequal pretreat-
ment symptoms in the two groups, and differences in sample
characteristics across the two groups. However, our results
provide initial proof‐of‐concept and suggest that a larger efficacy
trial is warranted.
A key innovation of this study was to develop a credible
placebo device that would isolate the effects of light treatment
from the stabilization of wake time, which also occurred as part of
the treatment. The use of neutral density filters dimmed the light
to a nontherapeutic level while maintaining a similar appearance
to the active Re‐timer®, including lighting up of the LEDs when the
placebo Re‐timer® was turned on. Although there was one
participant in the placebo group who reported low treatment
expectancy before treatment initiation, all participants reported
high perceived benefit at the end of treatment, suggesting that the
placebo was credible for participants. Moreover, all participants
who completed the anonymous feedback questionnaire thought
they were in the active group; this likely included participants who
had been in the placebo group.
There are several limitations to consider when interpreting the
results of this study. Because this was a pilot study, we evaluated
PTSD symptoms using a self‐report measure and did not conduct a
follow‐up assessment to establish whether the effects we found
were maintained over time. Clinician‐rated measures are consid-
ered the gold standard for diagnosing and evaluating PTSD. The
lack of a clinician‐rated measure may have contributed to the fact
that some participants' PTSD scores decreased before the
initiation of light treatment. However, this could also be because
of the measurement strategy used (i.e., use of a past month PCL‐5
score for the screening visit and a past week PCL‐5 score for pre‐
and post‐treatment visits) or positive expectancy about the receipt
of treatment. Because of the small sample size, our two groups
were not balanced with respect to pre‐treatment PTSD symptoms.
Participants in the active group were on average 8.9 points more
severe at pre‐treatment than participants in the placebo group. It
is possible that higher baseline scores in the active group could
have contributed to larger symptoms reductions. However, we did
see objective sleep changes in the active group relative to the
placebo group, suggesting there was a differential biological
impact of light in the two treatment groups. We excluded
participants with specific sleep disorders (sleep apnea, restless
leg syndrome) and substance use disorders because these
symptoms might interfere with our ability to detect treatment
effects. Given that these are common comorbid conditions for
individuals with PTSD (Chilcoat & Menard, 2003; Krakow, Ulibarri,
Moore, & McIver, 2015), this limits the generalizability of our
findings. Finally, only 60% of the participants responded to our
anonymous feedback survey.
TABLE 4 Changes in PTSD and depression by the treatment group
Active Placebo
Pre Post MCID Pre Post MCID
n M (SD) M (SD) n, % n M (SD) M (SD) n, % d
PCL‐5 9 43.11 (12.77) 28.00 (14.41) 6 (66.7) 6 34.17 (15.33) 31.67 (17.26) 2 (33.3) .94
PCL‐5 sensitivity analysisa 8 46.00 (10.03) 30.75 (11.30) 5 (62.5) 5 38.80 (11.52) 36.60 (13.78) 2 (40.0) .91
PHQ‐9 9 10.44 (4.33) 5.67 (3.94) 5 (55.6) 6 10.00 (4.43) 8.83 (5.81) 1 (16.7) .74
Note. MCID: minimal clinically important difference; PTSD: post‐traumatic stress disorder; Pre: retreatment visit 2. Post: post‐treatment visit 6. MCID:
minimal clinically important difference. PCL‐5: PTSD Checklist for DSM‐5; MCID: 10 points. PHQ‐9: Patient Health Questionnaire‐9; MCID: 5 points. d:
effect size of the difference between the active and placebo group in change from pre to post‐treatment (calculated as a change score); positive effect
sizes indicate greater improvement in the active compared to the placebo group.
aA sensitivity analysis was conducted examining only those who scored a minimum of 25 points on the PCL‐5 at visit 2.
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6 | CONCLUSION
With the poor uptake and limited efficacy of existing evidence‐based
treatments for PTSD, novel interventions are needed that are
acceptable and feasible for patients. Wearable bright light treat-
ments that are self‐administered have the potential to be easily
disseminable and scalable and might align well with patients'
priorities for treatment given that sleep disturbance is one of the
most common and pressing concerns among patients with PTSD
(McLay, Klam, & Volkert, 2010; Rosen, Adler, & Tiet, 2013). Previous
studies show that there is clear theoretical plausibility that morning
bright light could have therapeutic effects in patients with PTSD. Our
findings provide initial proof‐of‐concept regarding the acceptability,
feasibility, and efficacy of this treatment and suggest that the efficacy
of morning bright light for PTSD should be explored in a larger
randomized controlled trial.
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